Non-HDL and Calculated Components

Panels that include this biomarker

• Diabetes and ASCVD Risk Panel with Scores 92062

  7 analytes · Serum · Fasting not stated

  Method and collection

  Method

  Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)

  Preparation

  If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.

  Collection

  For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female) Race - African American: Y (for yes) or N (for no) Systolic Blood Pressure: mmHg Treatment for High B.P.: Y (for yes) or N (for no) Diabetes Status: Y (for yes) or N (for no) Smoking Status: Y (for yes) or N (for no)

  Reference notes

  See individual tests

  Quest Diagnostics catalog page

  Compare

• Diabetes Risk Panel with Score 92027

  7 analytes · Serum · Fasting not stated

  Method and collection

  Method

  Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)

  Preparation

  If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.

  Collection

  For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female)

  Reference notes

  See individual tests

  Quest Diagnostics catalog page

  Compare